New chemo formula aims to keep lung cancer away after surgery
NCT ID NCT06693336
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called SMS001, a new version of the chemotherapy paclitaxel, in 42 people with non-small cell lung cancer (stages Ib to IIIa). The goal is to see if a single dose after surgery can safely prevent the cancer from coming back. Researchers will monitor side effects and check for tumor recurrence in the chest.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SMS001 (a form of the chemotherapy drug paclitaxel)
- What this could lead to
- If it works, this could help prevent lung cancer from coming back after surgery, giving patients more time without recurrence.
- What could go wrong
- This is an early Phase IIa trial with only 42 participants, so results may not apply to everyone. The drug is a chemotherapy agent, which can cause side effects like low blood counts and nerve damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
Toronto General Hospital
RECRUITINGToronto, Ontario, M5G 2C4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.